Abstract
Analysis of 27,810 patients with advanced cancers treated with anti-PD-1/L1 therapies shows that immune gene signatures or immune cell infiltration is not universally associated with mutation burden or long-term survivors after immunotherapies across cancer entities. Thus, immunological stratification of tumors has limited bearing on the immunogenicity of tumors or immunotherapy outcomes.
Original language | English |
---|---|
Pages (from-to) | 1985-1987 |
Number of pages | 3 |
Journal | Cancer Cell |
Volume | 42 |
Issue number | 12 |
Early online date | Nov 13 2024 |
DOIs | |
State | Published - Dec 9 2024 |
Keywords
- B7-H1 Antigen/immunology
- Humans
- Immune Checkpoint Inhibitors/therapeutic use
- Immunotherapy/methods
- Lymphocyte Activation
- Lymphocytes, Tumor-Infiltrating/immunology
- Mutation
- Neoplasms/immunology
- Programmed Cell Death 1 Receptor/antagonists & inhibitors